An internal standard for the quantification of (±)-atenolol
| Cas No. | 1202864-50-3 |
| 别名 | 阿替洛尔D7,(RS)-Atenolol-d7 |
| Canonical SMILES | NC(CC1=CC=C(OCC(O)CNC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C=C1)=O |
| 分子式 | C14D7H15N2O3 |
| 分子量 | 273.4 |
| 溶解度 | Chloroform: slightly soluble,Methanol: slightly soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | (±)-Atenolol-d7is intended for use as an internal standard for the quantification of (±)-atenolol by GC- or LC-MS. (±)-Atenolol is an antagonist of the β1-adrenergic receptor (β1-AR; Ki= 1.14 µM).1It is selective for β1-ARs over β2-ARs (Ki= 48.7 µM). (±)-Atenolol (200 mg/kg per day) delays the onset of hypertension in spontaneously hypertensive rats.2Formulations containing atenolol have been used in the treatment of high blood pressure. 1.Golf, S., Bjornerheim, R., Erichsen, A., et al.Relative selectivity of different β-adrenoceptor antagonists for human heart β1- and β2-receptor subtypes assayed by a radioligand binding techniqueScand. J. Clin. Lab. Invest.47(7)719-723(1987)
2.Richer, C., Boissier, J.R., and Giudicelli, J.F.Chronic atenolol treatment and hypertension development in spontaneously hypertensive ratsEur. J. Pharmacol.47(4)393-400(1978) |
